Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TBPH 
Theravance Biopharma Inc (TBPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TBPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.4
1 Year Target Price $18.4
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.39% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 703.55M USD | Price to earnings Ratio 58.21 | 1Y Target Price 18.4 |
Price to earnings Ratio 58.21 | 1Y Target Price 18.4 | ||
Volume (30-day avg) 4 | Beta 0.01 | 52 Weeks Range 7.88 - 14.30 | Updated Date 08/29/2025 |
52 Weeks Range 7.88 - 14.30 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When After Market | Estimate 0.6731 | Actual -0.0842 |
Profitability
Profit Margin 16.88% | Operating Margin (TTM) -10.4% |
Management Effectiveness
Return on Assets (TTM) -5.65% | Return on Equity (TTM) 6.23% |
Valuation
Trailing PE 58.21 | Forward PE 9.43 | Enterprise Value 402638884 | Price to Sales(TTM) 9.11 |
Enterprise Value 402638884 | Price to Sales(TTM) 9.11 | ||
Enterprise Value to Revenue 5.22 | Enterprise Value to EBITDA 8.74 | Shares Outstanding 50361300 | Shares Floating 21894573 |
Shares Outstanding 50361300 | Shares Floating 21894573 | ||
Percent Insiders 4.37 | Percent Institutions 92.05 |
Upturn AI SWOT
Theravance Biopharma Inc
Company Overview
History and Background
Theravance Biopharma, Inc. was founded in 2014 as a spin-off from Theravance, Inc. The company focuses on the discovery, development, and commercialization of organ-selective medicines.
Core Business Areas
- Respiratory Disease: Developing and commercializing inhaled therapies for respiratory diseases like COPD and asthma.
- Gastrointestinal (GI) Disease: Developing and commercializing therapies for GI diseases.
Leadership and Structure
The company is led by a CEO and has a management team overseeing various departments including R&D, commercial operations, and finance. A board of directors provides governance and strategic oversight.
Top Products and Market Share
Key Offerings
- Yupelri (revefenacin): A once-daily nebulized bronchodilator for the maintenance treatment of COPD. While specific market share fluctuates, it competes with other long-acting bronchodilators. Competitors include Boehringer Ingelheim (Spiriva Respimat), AstraZeneca (Duaklir Genuair), and Sunovion Pharmaceuticals (Lonhala Magnair).
- Izba (ampreloxetine): A norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Competitors may include droxidopa and midodrine.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Respiratory and GI therapeutic areas are significant segments of the market.
Positioning
Theravance Biopharma focuses on organ-selective medicines, aiming for improved efficacy and reduced side effects. This strategy differentiates it from larger pharmaceutical companies with broader portfolios.
Total Addressable Market (TAM)
The TAM for COPD and nOH treatments is substantial, estimated to be in the billions of dollars globally. Theravance Biopharma's positioning targets specific segments within these larger markets.
Upturn SWOT Analysis
Strengths
- Organ-selective medicine approach
- Commercialized products
- Established R&D capabilities
- Experienced management team
Weaknesses
- Reliance on key products
- Limited financial resources compared to larger competitors
- High R&D risk
- Dependence on partners for some aspects of development and commercialization
Opportunities
- Expansion of existing product lines
- Development of new organ-selective therapies
- Strategic partnerships and acquisitions
- Increasing prevalence of respiratory and GI diseases
Threats
- Competition from established pharmaceutical companies
- Generic erosion of existing products
- Regulatory challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BHC
- AZN
- VRX
Competitive Landscape
Theravance Biopharma competes with larger pharmaceutical companies with more resources. Its advantage lies in its organ-selective approach and focus on specific therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the commercialization of Yupelri and development of other pipeline candidates. Specific growth rates depend on product sales and clinical trial progress.
Future Projections: Future growth depends on the success of pipeline candidates and market penetration of existing products. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include focusing on key development programs, expanding commercial reach for Yupelri, and seeking strategic partnerships.
Summary
Theravance Biopharma has strengths in organ-selective medicine and commercialized products, but it faces competition and R&D risks. It needs to expand its product lines and leverage partnerships to achieve sustained growth. Potential threats include generic erosion and regulatory challenges. Sustained growth is likely but uncertain due to the nature of clinical trails and market acceptance of its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Theravance Biopharma SEC Filings
- Company Investor Relations
- Third-party Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theravance Biopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-05-16 | CEO & Director Mr. Rick E. Winningham M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | Website https://www.theravance.com |
Full time employees 97 | Website https://www.theravance.com | ||
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.